Boceprevir Inhibitor

Name: Boceprevir Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5751453
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5751453

Boceprevir is a novel, potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with Ki of 14nM in both enzyme assay and EC90 of 350nM in cell-based replicon assay. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Boceprevir, Inhibitor

Full Product Name

Boceprevir

Product Synonym Names

SCH 503034; EBP 520

Form/Format

Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder; -80 degree C for 2 years in solvent
For obtaining a higher solubility, please warm the tube at 37 degree C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 degree C for several month.

Molecular Weight

519.68

Formula

C27H45N5O5

CAS

394730-60-0

Smiles

CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C

Receptor (IC50)

HCV NS3 protease: 14nM (Ki)

Solubility

DMSO: 91mg/mL (175.1mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Product Categories/Family for Boceprevir, inhibitor

Home; Microbiology & virology; HCV Protease

Product References and Citations for Boceprevir, inhibitor

1. Yao M, et al. Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A ProteaseActivity. PLoS One. 2016 Mar 4;11 (3):e20150894.
2. Coilly A, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother. 2012 Nov;56 (11):5728-34.
3. Burton MJ, et al. Telaprevir and boceprevir in african americans with genotype 1 chronic hepatitis C: implications for patients and providers. South Med J. 2012 Aug;105 (8):431-6.
4. Njoroge FG, et al. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res. 2008 Jan;41 (1):50-9.
5. Berenguer M, et al. New developments in the management of hepatitis C virus infection: focus on boceprevir. Biologics. 2012;6:249-56.

Other Notes

Small volumes of Boceprevir, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Boceprevir purchase

MBS5751453 is an inhibitor targeting Boceprevir.